Oral Semaglutide Pharmacokinetics, Safety, and Tolerability Investigated in Renal Impairment

Chronic kidney disease (CKD) affects millions globally, frequently co-occurring with type 2 diabetes (T2DM). Managing T2DM in CKD patients is complex, as many antidiabetic medications, especially peptide-based therapies, require dose adjustments due to altered drug clearance, impacting both efficacy and safety. Oral semaglutide, a potent GLP-1 receptor agonist, offers a non-injectable treatment option, but its pharmacokinetic profile and tolerability in individuals with varying degrees of renal impairment are not fully characterized. Understanding how kidney function influences oral semaglutide's disposition is crucial for establishing safe and effective dosing regimens, addressing a significant clinical need for this vulnerable patient population.

This Phase 1 clinical trial, conducted in Europe, was designed to thoroughly investigate the pharmacokinetics (PK), safety, and tolerability of oral semaglutide in subjects categorized by their renal function. The study enrolled participants across several groups: those with mild, moderate, and severe renal impairment, alongside a control group of subjects with normal renal function. While the specific dose of oral semaglutide, treatment duration, and the total number of participants (n) were not detailed in the abstract, the primary objectives included comprehensive assessment of drug exposure (e.g., AUC, Cmax), evaluation of adverse events, and overall tolerability across these distinct renal function cohorts. This parallel-group design allows for direct comparison of PK and safety profiles.